Publications by authors named "Howard L Kaufman"

100Publications

Clinical landscape of oncolytic virus research in 2020.

J Immunother Cancer 2020 Oct;8(2)

Surgery, Massachusetts General Hospital and Immuneering Corporation, Boston, Massachusetts, USA

View Article and Find Full Text PDF
October 2020

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.

Am J Clin Dermatol 2020 Dec;21(6):821-832

Division of Surgical Oncology, Massachusetts General Hospital, 55 Fruit Street, Warren 408C, Boston, MA, 02114, USA.

View Article and Find Full Text PDF
December 2020

Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.

Methods Enzymol 2020 18;635:167-184. Epub 2019 Oct 18.

Replimune Inc., Woburn, MA, United States; Massachusetts General Hospital, Boston, MA, United States. Electronic address:

View Article and Find Full Text PDF
October 2019

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.

Oncoimmunology 2019;8(7):1591875. Epub 2019 Apr 7.

Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article and Find Full Text PDF
April 2019

Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.

J Biol Methods 2019 4;6(2). Epub 2019 Apr 4.

Department of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA.

View Article and Find Full Text PDF
April 2019

Oncolytic Immunotherapy.

Surg Oncol Clin N Am 2019 07 5;28(3):419-430. Epub 2019 Apr 5.

Division of Surgical Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7B, Boston, MA 02114, USA; Replimune, Inc., Woburn, MA, USA. Electronic address:

View Article and Find Full Text PDF
July 2019

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade.

Oncoimmunology 2019;8(4):e1571390. Epub 2019 Feb 3.

Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article and Find Full Text PDF
February 2019

Two roads for oncolytic immunotherapy development.

J Immunother Cancer 2019 02 1;7(1):26. Epub 2019 Feb 1.

Rutgers Graduate School of Biomedical Sciences, New Brunswick, NJ, USA.

View Article and Find Full Text PDF
February 2019

Avelumab: is it time to get excited?

Expert Rev Anticancer Ther 2018 09 2;18(9):815-821. Epub 2018 Jul 2.

b Department of Medicine , Replimune Group Inc , Woburn , MA , USA.

View Article and Find Full Text PDF
September 2018

Management of Metastatic Melanoma in 2018.

JAMA Oncol 2018 06;4(6):857-858

Department of Medicine, Massachusetts General Hospital, Boston.

View Article and Find Full Text PDF
June 2018

Immunotherapy for Merkel cell carcinoma: a turning point in patient care.

J Immunother Cancer 2018 03 23;6(1):23. Epub 2018 Mar 23.

Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA.

View Article and Find Full Text PDF
March 2018

Unleashing the therapeutic potential of oncolytic viruses.

J Clin Invest 2018 04 5;128(4):1258-1260. Epub 2018 Mar 5.

Replimune Inc., Woburn, Massachusetts, USA.

View Article and Find Full Text PDF
April 2018

Metastasectomy following incomplete response to high-dose interleukin-2.

J Surg Oncol 2018 Mar 22;117(4):572-578. Epub 2017 Nov 22.

Division of Surgical Oncology, Rutgers University, New Brunswick, New Jersey.

View Article and Find Full Text PDF
March 2018

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Oncoimmunology 2017;6(10):e1338237. Epub 2017 Aug 31.

Department of Surgery and Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

View Article and Find Full Text PDF
August 2017

Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development.

Pigment Cell Melanoma Res 2018 03 15;31(2):241-252. Epub 2017 Nov 15.

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

View Article and Find Full Text PDF
March 2018

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

J Clin Oncol 2018 06 5;36(17):1658-1667. Epub 2017 Oct 5.

Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste Lebbé, Assistance Publique-Hôpital De Paris Dermatology and CIC Hôpital Saint Louis University Paris Diderot Sorbonne, Institut National de la Santé et de la Recherche Médicale U976, Paris, France; Robert H.I. Andtbacka, University of Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article and Find Full Text PDF
June 2018

Avelumab and other recent advances in Merkel cell carcinoma.

Future Oncol 2017 Dec 4;13(30):2771-2783. Epub 2017 Oct 4.

Departments of Surgery & Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.

View Article and Find Full Text PDF
December 2017

Finding gold in tumour immunotherapy.

Authors:
Howard L Kaufman

Lancet Oncol 2017 10;18(10):e561

Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA. Electronic address:

View Article and Find Full Text PDF
October 2017

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.

J Cutan Pathol 2018 Jan 26;45(1):48-53. Epub 2017 Oct 26.

Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

View Article and Find Full Text PDF
January 2018

High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.

Expert Opin Drug Saf 2017 Dec 21;16(12):1347-1357. Epub 2017 Sep 21.

a Departments of Surgery and Medicine, Rutgers Robert Wood Johnson Medical School , Rutgers University , New Brunswick , NJ , USA.

View Article and Find Full Text PDF
December 2017

Next generation approaches for tumor vaccination.

Chin Clin Oncol 2017 Apr;6(2):19

Tumor Vaccine Group, University of Washington, Seattle, WA, USA.

View Article and Find Full Text PDF
April 2017

Rational Combination Immunotherapy: Understand the Biology.

Authors:
Howard L Kaufman

Cancer Immunol Res 2017 05;5(5):355-356

Departments of Surgery and Medicine, Rutgers University, New Brunswick, New Jersey.

View Article and Find Full Text PDF
May 2017

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Future Oncol 2017 Jun 28;13(14):1263-1279. Epub 2017 Mar 28.

Translational Skin Cancer Research, German Cancer Consortium (DKTK), Partner site Essen Düsseldorf, University Hospital Essen, Essen, Germany.

View Article and Find Full Text PDF
June 2017

Combination immunotherapy: a road map.

J Immunother Cancer 2017 21;5:16. Epub 2017 Feb 21.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Z-1503, New York, NY 10065 USA.

View Article and Find Full Text PDF
June 2018

Intratumoral Approaches for the Treatment of Melanoma.

Cancer J 2017 Jan/Feb;23(1):40-47

From the Departments of *Surgery and †Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article and Find Full Text PDF
August 2017

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.

Am J Clin Dermatol 2017 Feb;18(1):1-15

Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, Room 2004, New Brunswick, NJ, 08901, USA.

View Article and Find Full Text PDF
February 2017

Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.

Cancer Immunol Immunother 2017 01 18;66(1):9-16. Epub 2016 Oct 18.

Division of Surgical Oncology Research, Section of Surgical Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08903, USA.

View Article and Find Full Text PDF
January 2017

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.

J Immunother Cancer 2016 20;4:53. Epub 2016 Sep 20.

Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, Room 2508B, New Brunswick, NJ 08901 USA.

View Article and Find Full Text PDF
September 2016

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.

Cancer 2016 Nov 6;122(22):3576-3577. Epub 2016 Aug 6.

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.

View Article and Find Full Text PDF
November 2016

Cancer immunotherapy trials: leading a paradigm shift in drug development.

J Immunother Cancer 2016 19;4:42. Epub 2016 Jul 19.

Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ USA.

View Article and Find Full Text PDF
July 2016

IFN-λ cancer immunotherapy: new kid on the block.

Immunotherapy 2016 07;8(8):877-88

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, PA, USA.

View Article and Find Full Text PDF
July 2016

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

J Clin Oncol 2016 08 13;34(22):2619-26. Epub 2016 Jun 13.

Igor Puzanov, Vanderbilt University, Nashville, TN; Mohammed M. Milhem, University of Iowa, Iowa City, IA; David Minor, California Pacific Melanoma Center, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; and Ai Li, Lisa Chen, Michael Chastain, Kevin S. Gorski, Abraham Anderson, and Jeffrey Chou, Amgen, Thousand Oaks, CA; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; and Robert H.I. Andtbacka, University of Utah, Salt Lake City, UT.

View Article and Find Full Text PDF
August 2016

Biomarkers for Immunotherapy: Current Developments and Challenges.

Am Soc Clin Oncol Educ Book 2016 ;35:e493-503

From the Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article and Find Full Text PDF
January 2017

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.

Clin Cancer Res 2016 Mar 30;22(5):1048-54. Epub 2015 Dec 30.

Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

View Article and Find Full Text PDF
March 2016

Surgical Management of Melanoma.

Cancer Treat Res 2016 ;167:149-79

Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany St., Suite 3001, New Brunswick, NJ, 08901, USA.

View Article and Find Full Text PDF
January 2016

Oncolytic viruses: a new class of immunotherapy drugs.

Nat Rev Drug Discov 2015 09;14(9):642-62

Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, Room 2004, New Brunswick, New Jersey 08901, USA.

View Article and Find Full Text PDF
September 2015

Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.

JAMA Oncol 2015 Aug;1(5):668-76

Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick.

View Article and Find Full Text PDF
August 2015

Combination Immunotherapy for Melanoma.

Authors:
Howard L Kaufman

JAMA Oncol 2015 Jun;1(3):387-8

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

View Article and Find Full Text PDF
June 2015

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

J Clin Oncol 2015 Sep 26;33(25):2780-8. Epub 2015 May 26.

Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma Center, San Francisco; Gregory A. Daniels, University of California San Diego Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University Hospital and Health Network, Bethlehem, and Temple University School of Medicine, Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, Washington University School of Medicine, St Louis, MO; Kevin Harrington, Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, National Institute for Health Research Biomedical Research Centre, Oxford, United Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.

View Article and Find Full Text PDF
September 2015

Oncolytic virus immunotherapy for melanoma.

Curr Treat Options Oncol 2015 Mar;16(3):326

Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, Room 2004, New Brunswick, NJ, 08901, USA.

View Article and Find Full Text PDF
March 2015

Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.

J Med Microbiol 2015 Feb;64(Pt 2):164-73

Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL, USA Rush University Cancer Center, Rush University Medical Center, Chicago, IL, USA

View Article and Find Full Text PDF
February 2015

Precision immunology: the promise of immunotherapy for the treatment of cancer.

Authors:
Howard L Kaufman

J Clin Oncol 2015 Apr 20;33(12):1315-7. Epub 2015 Jan 20.

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

View Article and Find Full Text PDF
April 2015

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

J Pers Med 2014 Mar 7;4(1):52-64. Epub 2014 Mar 7.

Duke University Medical Center, 10 Bryan Searle Drive, Mudd Building, Rm 437, Durham, NC 27710, USA.

View Article and Find Full Text PDF
March 2014

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014.

J Immunother Cancer 2014 Sep 16;2(1):26. Epub 2014 Sep 16.

Deputy Director, Professor of Medicine, Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Rd NW, NRB-E501, Washington, 20057, DC, USA.

View Article and Find Full Text PDF
September 2014

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.

J Immunother Cancer 2014 18;2:20. Epub 2014 Jun 18.

Duke University Medical Center, Mudd Building, Rm 437, 10 Bryan Searle Drive, Durham, NC 27710, USA.

View Article and Find Full Text PDF
July 2014

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.

J Immunother Cancer 2014 13;2:11. Epub 2014 May 13.

University of Virginia, P.O. Box 800709, Charlottesville, VA 22908, USA.

View Article and Find Full Text PDF
June 2014

High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis.

J Interferon Cytokine Res 2014 Nov 25;34(11):915-9. Epub 2014 Jun 25.

1 Department of Immunology/Microbiology, Rush University Medical Center , Chicago, Illinois.

View Article and Find Full Text PDF
November 2014

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.

J Transl Med 2014 May 6;12:113. Epub 2014 May 6.

Rutgers Cancer Institute of New Jersey, Rutgers University, 195 Little Albany Street, Room 2007, New Brunswick, NJ 08901, USA.

View Article and Find Full Text PDF
May 2014